semaxanib-resistant FLT3 mutants

Stable Identifier
R-HSA-9702577
Type
Pathway
Species
Homo sapiens
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this pathway in the Pathway Browser

Semaxanib, also known as SU5614, is an investigational type I tyrosine kinase inhibitor with activity against a wide range of receptor tyrosine kinases. It is not currently approved for clinical use. This pathway describes FLT3 mutants that show resistance to semaxanib-mediated inhibition (Yee et al, 2002; Spiekermann et al, 2003).

Literature References
PubMed ID Title Journal Year
12351406 SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase

Yee, KW, O'Farrell, AM, Smolich, BD, Cherrington, JM, McMahon, G, Wait, CL, McGreevey, LS, Griffith, DJ, Heinrich, MC

Blood 2002
12406902 The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3

Spiekermann, K, Dirschinger, RJ, Schwab, R, Bagrintseva, K, Faber, F, Buske, C, Schnittger, S, Kelly, LM, Gilliland, DG, Hiddemann, W

Blood 2003
Participants
Participant Of
Disease
Name Identifier Synonyms
cancer 162 malignant tumor, malignant neoplasm, primary cancer
Authored
Reviewed
Created
Cite Us!